Vendor Intelligence Report: Hong Kong Lemite Group Limited

Published 3 Jul 2026. 18-page investigative report on who is behind Hong Kong Lemite Group Limited: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Hong Kong Lemite Group Limited's overall pass rate is 75%: 3 pass and 1 fail. The dataset covers one product, Retatrutide, so the useful signal is narrow. Lemite is better evidenced than a blind B2B broker, but the short record and one failure keep it in a cautious middle tier that requires lot-specific verification.

The identity layer is the larger concern. The public Hong Kong name did not resolve in Hong Kong Companies Registry or OpenCorporates searches, no directors or staff surfaced, and the supplied Global Sources manufacturer page returned blank. Investigators instead anchored the live footprint to lemitebio.com and ECHEMI, where the profile reads as a recent Trader rather than a proven manufacturer.

Web infrastructure reinforces the recourse problem. Lemitebio.com was registered in Oct. 2024 through Xiamen 35.com with private registrant details and 4cun.com nameservers; the archive trail contains only July 2025 captures. The positive offset is limited: the X/web sweep did not surface coupon-code promoters or referral traffic, but the payment rails, source lab, and actual legal operating entity remain open leads.

Inside the full report:

  • Appendix A Finnrick laboratory data, rating overview, trajectory grid, and methodology-divergence views for the single tested product
  • Hong Kong Companies Registry and OpenCorporates search trail for Hong Kong Lemite Group Limited and Lemite Group Limited
  • Global Sources dead-link exhibit alongside lemitebio.com homepage, About Us, and products-page captures
  • WHOIS and domain-infrastructure analysis covering Xiamen 35.com, private registrant data, 4cun.com nameservers, and Wayback history
  • ECHEMI trader-profile analysis comparing Lemite's leading-enterprise posture with the documented 2024 footprint
  • Affiliate and promotion sweep across X, web coupon pages, and Reddit, with coverage caveats

Risk assessment

  • Corporate identity and recourse risk — high: No registry match for the public Hong Kong name, private WHOIS, dead listed Global Sources page, and no identified personnel leave buyers without a verifiable counterparty.
  • Manufacturer and source-lab opacity risk — medium: ECHEMI lists the vendor as a Trader; source labs for Retatrutide and other Lemite peptides are undisclosed.
  • Misleading history-claim risk — medium: Leading-enterprise posture is not corroborated by the 2024 ECHEMI/domain footprint, sparse Wayback record, or registry searches.
  • Retatrutide batch-consistency risk — medium: Retatrutide has 4 Finnrick tests with 3 pass / 1 fail and a 78.8% rating, so lot-specific verification is warranted.